Diabetes Drug Glitazones May Prevent Parkinson’s Disease

July 22, 2015: New research shows that a type of diabetes drug, called Glitazones, may offer some hope for the treatment for Parkinson’s disease.

The research was published in PLoS One Journal, said a report on BBC.

Scientists found that people who are taking Glitazones pills, meant for diabetes, are less likely to have Parkinson’s disease as compared to others who are using different diabetes pills.

However, scientists of the research have warned that the drugs may have serious side-effects and must not be prescribed for healthy individuals.

What the researchers agreed on is the use of findings for discovering more things about the treatment of Parkinson’s.

Parkinson’s disease is found in about 127,000 people in the UK alone. The condition is characterized by slow movements, tremors, and muscle stiffness.

There are no prescribed or proven drugs against the condition, which demands more work and research.

The new study was relying on data from people, who had diabetes but not Parkinson’s disease, and researchers compared the records of 44,597 people using Glitazones pills for diabetes with 120,373 people on other prescribed diabetes pills.

It was found that people had drugs off the Glitazone group didn’t not develop Parkinson’s- at least the numbers were lesser.

However, there were no long term benefits as when the patients who switched the drug to something else, the shield from the nerve problem was missing.

London School of Hygiene and Tropical Medicine’s Lead researcher Dr Ian Douglas was quoted saying that sometimes drugs can have “unintended beneficial effects”.

He also added that such treatments may work in the early stages of Parkinson’s when the nerve damage is limited.